This trend was also seen when disease-specific death was compared: Patients who had TP53 mutations in L2, L3 and LSH motifs died of cancer more often (7 out of 9 cases, 77.7%), than patients with a wild-type p53 in their tumour (8 out of 19, 42.1%) or patients with tumours presenting a mutation outside L2/L3/LSH domain (2 out of 8 cases, 25%). Here, TP53 is linked to neoplasm.